Hemophilia A and von Willebrand deficiency: therapeutic implications. Issue 6 (August 2020)

• Record Type: Journal Article
• Authors: Basso, Maria; Lazzareschi, Ilaria; Curatola, Antonietta; Di Gennaro, Leonardo; Buonsenso, Danilo; Gatto, Antonio; De Candia, Erica; De Cristofaro, Raimondo
• Is Part Of: Blood coagulation and fibrinolysis. Volume 31:Issue 6(2020)
• Publication Date: 2020-08
• Subjects: factor VIII -- hemophilia A -- von Willebrand antigen; Blood -- Coagulation -- Periodicals; Fibrinolysis -- Periodicals; Hemostasis -- Periodicals; Thrombosis -- Periodicals; Blood Coagulation -- Periodicals; Fibrinolysis -- Periodicals; Hemostasis -- Periodicals; Thrombosis -- Periodicals; 612.115
• DOI: 10.1097/MBC.0000000000000908
• Languages: English
• ISSNs: 0957-5235

Abstract

Abstract : N/A: Hemophilia A is an X-linked bleeding disorder caused by a deficiency of factor VIII. Depending on the factor VIII activity in patient's plasma, we can have three different forms of hemophilia A: mild (5–40 IU/dl), moderate (1–5 IU/dl) and severe (<1 IU/dl). The most common symptoms include recurrent bleeding episodes of soft tissues and joints. The treatment is based on the prophylactic use of clotting factor concentrates to prevent bleeding episodes. We describe three cases of patients with initially diagnosis of hemophilia A that show different clinical severity, undergoing prophylactic therapies with low benefit. In these patients, the dosage of von Willebrand antigen revealed either low level or absence of this factor, which in one case was caused by the occurrence of a type III form of von Willebrand disease.